BCX17725 + Placebo
Phase 1Recruiting 0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Netherton Syndrome
Conditions
Netherton Syndrome
Trial Timeline
Sep 26, 2024 → Dec 1, 2026
NCT ID
NCT06539507About BCX17725 + Placebo
BCX17725 + Placebo is a phase 1 stage product being developed by BioCryst Pharmaceuticals for Netherton Syndrome. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06539507. Target conditions include Netherton Syndrome.
Hype Score Breakdown
Clinical
6
Activity
15
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06539507 | Phase 1 | Recruiting |
Competing Products
8 competing products in Netherton Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| DS-2325a | Daiichi Sankyo | Phase 1/2 | 24 |
| DS-2325a + DS-2325a + Placebo + Placebo | Daiichi Sankyo | Phase 1 | 29 |
| DS-2325a + Placebo | Daiichi Sankyo | Phase 1 | 29 |
| Pimecrolimus 1% Cream | Novartis | Phase 1/2 | 32 |
| QRX003-2% Lotion + QRX003-4% Lotion QAM + Vehicle + QRX003-4% Lotion BID | Quoin Pharmaceuticals | Phase 2/3 | 32 |
| QRX003, 4% Lotion | Quoin Pharmaceuticals | Phase 2/3 | 35 |
| QRX003, 4% Lotion | Quoin Pharmaceuticals | Phase 2/3 | 35 |
| ATR12-351 | Azitra | Phase 1 | 26 |